Abstract 5351
Background
The diagnosis of incidental or unsuspected pulmonary embolism (PE) in cancer outpatients undergoing scheduled CT-scans is a challenge in daily oncological practice. The aim of this study was to assess the performance of the ‘4S rule’ (Setting, Suspicion, Signs and Symptoms) as a PE risk-assessment model in this setting.
Methods
We assessed consecutive patients with cancer-associated PE from an ongoing multicenter observational registry (2005-2018). Patients were classified as presenting ‘Truly asymptomatic unsuspected PE’ (TAUPE) according to the ‘4S rule’ (EurRespir J 2017;49(1):1600282 and EurRespir J 2017;49(1):1602225) that includes the following variables: (1) outpatient Setting at PE diagnosis; (2) no Suspicion of PE; (3) vital Signs within normal limits including blood pressure >100 mmHg, heart rate <100 per minute and oxygen saturation >95%; and (4) absence of PE Symptoms. Short-term outcome measures included: all-cause and PE-related mortality within 30 days after the index PE.
Results
We evaluated a total of 617 patients (61.6% male; median age 65 + 11.4 years) including 207 (33%) with TAUPE, 284 (47%) with ‘acute suspected PE’ and 126 (20%) with ‘unsuspected PE with symptoms’. Most patients (79%) had metastatic cancer and nearly half (47%) were on chemotherapy. The PE was incidentally found in 54% of the cohort. The most frequent tumors were: 32% lung, 14% colorectal, 13% urological, and 12% upper gastrointestinal. All-cause 30-day mortality occurred in 95 patients (15% of the cohort) and 12 cases presented PE-related mortality (2% of the cohort). Patients with TAUPE had lower all-cause 30-day mortality compared to non-TAUPE cases (3% vs. 22%; p < 0.0001). PE-related 30-day mortality occurred in 0 patients with TAUPE and in 12 (3%) non-TAUPE patients (0% vs. 3%; p = 0.013).
Conclusions
Short-term mortality in patients with cancer-associated PE is high. Cancer outpatients with TAUPE according to the 4S rule criteria (33% in the cohort) were identified as a low-risk group of all-cause and PE-related short-term mortality. These findings may help to develop PE risk-assessment models in this setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Clinic de Barcelona.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4615 - Proteomic Profiling Identifies Molecular Basis of Adverse Event to BPM31510 Exposure: Rationale for Comprehensive Molecular Pharmacodynamics (PD) in Phase 1 Clinical Trial Design
Presenter: Vivek Subbiah
Session: Poster Display session 1
Resources:
Abstract
5052 - Identification of first-in-class, naturally occurring LAG3 checkpoint inhibitor
Presenter: Gennady Bratslavsky
Session: Poster Display session 1
Resources:
Abstract
5336 - Are Epigenetic therapies modifying sensitivity to conventional chemotherapy?
Presenter: Alexandra Bizot
Session: Poster Display session 1
Resources:
Abstract
5739 - Oncogenic mutations at the dimer interface of EGFR lead to formation of covalent homo-dimers and allosteric activation of the kinase domain: A mechanism which alters the selectivity profile of oncogenic EGFR.
Presenter: Elizabeth Buck
Session: Poster Display session 1
Resources:
Abstract
5492 - Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer
Presenter: Rui Xiong
Session: Poster Display session 1
Resources:
Abstract
5965 - EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
Presenter: Ronan Le Moigne
Session: Poster Display session 1
Resources:
Abstract
3582 - AVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumors, and sensitizes tumors to immune checkpoint inhibitors.
Presenter: Tina Gruosso
Session: Poster Display session 1
Resources:
Abstract
1996 - High NAMPT expression and anti-tumor activity of NAMPT inhibitor in adult T-cell leukemia/lymphoma
Presenter: Tomohiro Kozako
Session: Poster Display session 1
Resources:
Abstract
4307 - TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers
Presenter: Alexander Drilon
Session: Poster Display session 1
Resources:
Abstract
4869 - In Vivo Evaluation of Cisplatin-loaded PEG-PCL Block Copolymeric Nanoparticles for Anticancer Drug Delivery
Presenter: Yingtzu Yen
Session: Poster Display session 1
Resources:
Abstract